JP2024505517A - 製剤 - Google Patents

製剤 Download PDF

Info

Publication number
JP2024505517A
JP2024505517A JP2023545783A JP2023545783A JP2024505517A JP 2024505517 A JP2024505517 A JP 2024505517A JP 2023545783 A JP2023545783 A JP 2023545783A JP 2023545783 A JP2023545783 A JP 2023545783A JP 2024505517 A JP2024505517 A JP 2024505517A
Authority
JP
Japan
Prior art keywords
formulation
composition
pilocarpine
manufactured
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505517A5 (cg-RX-API-DMAC7.html
Inventor
リウ,シャオジュン・マイケル
シーア,ジェームズ・ジェーン-グオ
セーケイ,ガブリエラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaukos Corp
Original Assignee
Glaukos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaukos Corp filed Critical Glaukos Corp
Publication of JP2024505517A publication Critical patent/JP2024505517A/ja
Publication of JP2024505517A5 publication Critical patent/JP2024505517A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023545783A 2021-01-28 2022-01-28 製剤 Pending JP2024505517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142889P 2021-01-28 2021-01-28
US63/142,889 2021-01-28
PCT/US2022/014317 WO2022165178A1 (en) 2021-01-28 2022-01-28 Formulations

Publications (2)

Publication Number Publication Date
JP2024505517A true JP2024505517A (ja) 2024-02-06
JP2024505517A5 JP2024505517A5 (cg-RX-API-DMAC7.html) 2025-01-16

Family

ID=82494246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545783A Pending JP2024505517A (ja) 2021-01-28 2022-01-28 製剤

Country Status (6)

Country Link
US (3) US11872213B2 (cg-RX-API-DMAC7.html)
EP (1) EP4284362A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505517A (cg-RX-API-DMAC7.html)
AU (1) AU2022212108A1 (cg-RX-API-DMAC7.html)
CA (1) CA3210064A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022165178A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160668A1 (en) 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US11872213B2 (en) 2021-01-28 2024-01-16 Glaukos Corporation Formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180333414A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
US20190262290A1 (en) * 2016-10-12 2019-08-29 Ps Therapies Ltd Drug vehicle compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
ES2752008T3 (es) * 2009-10-30 2020-04-02 Intratus Inc Métodos y composiciones para la liberación sostenida de fármacos
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) * 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
JP6946575B2 (ja) * 2018-04-24 2021-10-06 アラーガン、インコーポレイテッドAllergan,Incorporated 眼の状態の治療のためのピロカルピン塩酸塩の使用
US11872213B2 (en) 2021-01-28 2024-01-16 Glaukos Corporation Formulations
WO2024026365A1 (en) * 2022-07-26 2024-02-01 Glaukos Corporation Ophthalmic topical cream formulations and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190262290A1 (en) * 2016-10-12 2019-08-29 Ps Therapies Ltd Drug vehicle compositions and methods of use thereof
US20180333414A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use

Also Published As

Publication number Publication date
US20220233506A1 (en) 2022-07-28
WO2022165178A1 (en) 2022-08-04
EP4284362A4 (en) 2024-12-25
US20260124179A1 (en) 2026-05-07
US11872213B2 (en) 2024-01-16
WO2022165178A9 (en) 2022-10-13
US20240115551A1 (en) 2024-04-11
CA3210064A1 (en) 2022-08-04
AU2022212108A1 (en) 2023-08-17
AU2022212108A9 (en) 2024-05-09
US12533344B2 (en) 2026-01-27
EP4284362A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
CN119546278A (zh) 两性离子在眼用局部乳膏组合物和制剂中的新应用
US20260124179A1 (en) Formulations
CA2784492C (en) Non-irritating ophthalmic povidone-iodine compositions
TWI827800B (zh) 4-(7-羥基-2-異丙基-4-側氧基-4h-喹唑啉-3-基)-苄腈之配製物
WO2016016908A1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
CN109966245A (zh) 一种酒石酸溴莫尼定结冷胶型原位凝胶滴眼液及制备方法
CN101977630B (zh) 眼药组合物
CA2819628A1 (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
JP2017527600A5 (cg-RX-API-DMAC7.html)
EP2379078A2 (en) Topical formulations of flap inhibitors for administration to an eye
CN115487139B (zh) 一种葛根素结冷胶离子型原位凝胶滴眼液及制备方法
CA2851492A1 (en) Ophthalmic gel compositions
CN104721136A (zh) 一种布佐林胺眼用纳米混悬剂及其制备方法
CN102198087B (zh) 一种不含防腐剂的眼用原位胶凝剂及其制备方法
JP2025513344A5 (cg-RX-API-DMAC7.html)
CN102018656A (zh) 含有效成分拉坦前列素的眼用凝胶剂及其制备方法
JPH01294633A (ja) 点眼剤
HK40128453A (en) Compositions and methods for the treatment of presbyopia
Arif et al. THE EFFECTS OF DIFFERENT PHYSICAL PROPERTIES OF ARTIFICIAL TEARS ON SUBJECTIVE OCULAR SENSATION
WO2024240216A9 (zh) 一种有效延缓及治疗近视的药物组合物
AU2023255001A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
CA3217868A1 (en) Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin
HK40109101A (en) A pharmaceutical composition for effectively delaying and treating myopia
JP2021517139A (ja) 選択的syk阻害剤の使用方法および医薬組成物
JP2016222563A (ja) 網膜色素変性処置用眼科用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260629